KIN1408

KIN1408

Biochem/physiol Actions

KIN1408 is a small molecule that targets factors at or above the level of MAVS in the RLR signaling pathway to drive IRF3 activation (IRF3 nuclear translocation ECmax = 5 µM in 20 h; Huh7 cells) without significant cytotoxicity (50 µM/20 h in Huh7 or 20 µM/36 h in HEK293 cultures). KIN1408 induces cellular transcription of innate immune genes (Eff. conc. 1.25-20 µM in 20 h; PMA-differentiated THP-1 cells) in a MAVS- and IRF3-dependent manner and exhibits broad-spectrum anti-viral activity (Eff. conc. 1-5 µM), including dengue virus 2 (DV2; Huh7), influenza A (IAV H3N2; HEK293), RSV (A2 strain; HeLa), Ebola (EBOV strain Zaire; HUVECs), Nipah virus (NiV; HUVECs), and Lassa virus (LASV; HUVECs). MAVS signaling activation upon Zika virus infection or KIN1408 treatment is reported to result in pTBK1 mitochondria relocalization and caspase 3-mediated apoptosis in human neuroepithelial stem (NES) cells.

Packaging

5, 25 mg in glass bottle

No detailed specifications are available for this product.

There are no downloads for this product.

Code Description Colour Quality Level Manufacturer Storage Temp. Solubility Form Assay Price Quantity
3575478 KIN1408 white to beige 100 SIGMA-ALDRICH 2-8°C
£435.96 (exc VAT) per 25MG
-
+
3575479 KIN1408 white to beige 100 SIGMA-ALDRICH 2-8°C
£121.32 (exc VAT) per 5MG
-
+